RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.» Read More
Despite disappointing trial results on Friday, the CEO of Bristol-Myers remains optimistic.
Top technician Carter Worth says Apple and biotech look "married." He explains why they are the must-own names in the market right now.
Giovanni Caforio, Bristol-Myers Squibb CEO, joins CNBC's Meg Tirrell to discuss data in lung cancer and the importance of valuable medicines becoming available to patients.
CNBC's Meg Tirrell has the update on the latest development from this year's American Society of Clinical Oncology meeting.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
There have only been four flu pandemics since the start of the 20th century, yet concerns are widening about the potential for a new outbreak.
As of now, 24 laboratories in 11 states and two foreign countries are believed to have received suspect samples, the Pentagon said.
Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.
A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.
Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
CNBC's Meg Tirrell, provides a preview of this weekend's meeting of the American Society of Clinical Oncology and which big pharma companies investors need to watch come Monday.
Michael Mussallem, Edwards Lifesciences CEO, provides insight into the future of treating heart disease.
Michael Mussallem, Edwards Lifesciences CEO, discusses major strides the medical community has made in cardiovascular treatment.
Pfizer reportedly approached Cellectis with a deal that could value it at about $1.64 billion, the Financial Times reported.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
A major drug prescription benefits manager is pushing to change the skyrocketing pricing structure, reports CNBC's Meg Tirrell
Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.
Cowen's David Seaburg has a very interesting way to play biotech and pharma stocks now.
In the world's fight against antibiotic resistance, Bayer CEO Marijn Dekkers sees the need for a global antibiotics bailout.
Get the best of CNBC in your inbox